长春高新：子公司GenSci134注射液临床试验获批

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci134 injection, which is intended for treating children with growth retardation due to endogenous growth hormone deficiency [1] Group 1 - The clinical trial application for GenSci134 injection has been accepted, indicating progress in the drug development process [1] - The drug is specifically aimed at treating idiopathic short stature (ISS) in children, addressing a significant medical need in this demographic [1]